RxDoctor Payments Data

Wendy Hartsoe

Family · Granite Falls, NCNPI 1639585151

Payments from drug & device makers

$6,307in general payments, 2019–2025

Across 369 payments — averaging $17.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$670
  • AstraZeneca$525
  • Pfizer$488
  • GSK$476
  • Exact Sciences$273
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$6,307100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,307 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$23,629
Medicare patients
100
Services billed
434

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide73$122,560
Tresiba Flextouch U-200Insulin Degludec45$68,369
JardianceEmpagliflozin54$64,178
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$52,558
MounjaroTirzepatide34$40,016
EliquisApixaban43$38,078
VraylarCariprazine Hcl26$35,901
RybelsusSemaglutide20$30,239
FarxigaDapagliflozin Propanediol24$28,667
MyrbetriqMirabegron23$23,110
Breztri AerosphereBudesonide/Glycopyr/Formoterol25$17,149
JanuviaSitagliptin Phosphate11$12,381
Tresiba Flextouch U-100Insulin Degludec21$11,102
Dexlansoprazole DrDexlansoprazole30$9,384
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,317

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$670$152,79993 claims
Boehringer IngelheimJardiance$156$64,17854 claims
GSKTrelegy Ellipta, Anoro Ellipta$476$60,87591 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$525$52,67061 claims
Lilly USA, LLCMounjaro$183$40,01634 claims
PfizerEliquis$488$38,07843 claims
AbbVieVraylar, Synthroid$1,463$37,56740 claims
Astellas Pharma US IncMyrbetriq$29$23,11023 claims
MerckJanuvia$77$12,38111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.

Other family in Granite Falls

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →